Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.52 |
| ▸ | TK2 | O00142 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2920443 | 1.00 | TK1 (0.52) | TK1TK2LMNASMN1; SMN2 | |
| SCHEMBL1129570 | 0.86 | LMNA (0.55) | TK1LMNA | |
| SCHEMBL6314490 | 0.86 | LMNA (0.55) | TK1LMNA | |
| SCHEMBL1129572 | 0.86 | LMNA (0.55) | TK1LMNA | |
| SCHEMBL7701755 | 0.86 | LMNA (0.55) | TK1LMNA | |
| SCHEMBL6760136 | 0.86 | LMNA (0.55) | TK1LMNA | |
| SCHEMBL1130181 | 0.86 | LMNA (0.55) | TK1LMNA | |
| SCHEMBL6753208 | 0.83 | SMN1; SMN2 (0.54) | TK1LMNASMN1; SMN2 | |
| SCHEMBL1027300 | 0.83 | TK1 (0.60) | TK1TK2LMNASMN1; SMN2 | |
| SCHEMBL6752642 | 0.83 | LMNA (0.60) | TK1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204415-B1 | 5-(E)-BROMOVINYL URACIL ANALOGUES AND RELATED PYRIMIDINE NUCLEOSIDES AS ANTI-VIRAL AGENTS AND METHODS OF USE | UNIV YALE (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20040053891-A1 | 5-(E)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-18 | — | — | US | disclosed |
| US-6653318-B1 | Varicella zoster and epstein barr viruses | YALE UNIVERSITY | 2003-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053891-A1 | 5-(E)-bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use | TYMP, DPYD, CXCL8 | TK1 19/4885TK2 85/4885LMNA 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.